High-bioavailability sodium crocetin nano complex preparation, preparation method, medicine and application
By loading sodium saffronate with nanomaterial carriers, the problems of its instability and low bioavailability in solution were solved, and efficient oral delivery and sustained release effects were achieved, which significantly improved the heart failure and cardiovascular disease. Treatment effect.
Patent Information
- Application Number
- CN202410078631.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-01-18
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2044-01-18
AI Technical Summary
Sodium saffronate is unstable in solution and has low bioavailability, making it difficult to develop as an oral preparation and has high production costs, which affects the drug properties.
Using nanomaterials as drug carriers, the high-bioavailability sodium saffronate nanocomplex preparations have been developed through efficient loading and effective release of sodium saffronate, including polymer nanocarriers, lipid nanocarriers or inorganic nanoparticle carriers. , improve the stability and absorption efficiency of drugs.
It significantly improves the stability and bioavailability of the drug, delays myocardial fibrosis, improves heart failure, expands clinical value and drug properties, and reduces toxic side effects on normal cells or tissues.
Smart Images

Figure CN118924914A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to a sodium crocetin nano complex preparation with high bioavailability, a preparation method, a medicine and application. Background Art
[0002] Patients with underlying cardiovascular diseases, especially those with ischemic heart disease and hypertensive heart disease, have a high probability of developing heart failure syndrome as they age. Chronic heart failure (CHF) refers to the gradual onset of heart failure symptoms and signs on the basis of existing chronic heart disease. At present, the treatment strategy for heart failure, which aims to change the biological properties of the failing heart, has gradually shifted from short-term hemodynamic / pharmacological measures such as diuresis, cardiotonic, and vasodilation to long-term, restorative measures based on neuroendocrine inhibitors. Traditional Chinese medicine has advantages in delaying the disease, improving cardiac function, and improving the quality of life. It is also characterized by low cost, wide applicability, and few side effects. It is generally considered to be an alternative strategy for the treatment of heart failure (HF), especially CHF.
[0003] Myocardial ischemia refers to a pathological state in which the blood perfusion of the heart is reduced, resulting in a decrease in the oxygen supply to the heart, abnormal myocardial energy metabolism, and inability to support the normal functioning of the heart. The energy required for cardiac activity is almost entirely provided by aerobic metabolism, so even when at rest, the myocardial blood oxygen uptake rate is very high (about 70%). Under normal circumstances, the body can regulate itself to ensure that the blood supply and demand are relatively constant to ensure the normal functioning of the heart. When some reason causes an imbalance in the blood supply and demand of the myocardium, it constitutes true myocardial ischemia. Coronary heart disease is the main and most common cause of myocardial ischemia. In addition, myocardial damage refers to organic heart disease, such as heart disease. Clinically, coronary heart disease, angina pectoris, myocarditis and myocardial infarction are common diseases of myocardial damage. Its symptoms mainly have three stages. The first stage is myocardial ischemia, the second stage is myocardial damage, and the third stage is myocardial necrosis. Myocardial fibrosis, also known as myocardial calcification, is the result of persistent and / or repeated myocardial ischemia and hypoxia caused by moderate to severe coronary atherosclerotic stenosis, leading to the gradual development of heart failure, i.e. chronic ischemic heart disease.
[0004] Crocetin, also known as saffron acid or crocetin, is the main active ingredient of the traditional Chinese medicine saffron and gardenia. It is a natural carotenoid dicarboxylic acid. It has strong pharmacological activities such as anti-myocardial ischemia, antioxidant, and anti-cardiac hypertrophy. Crocetin significantly reduces cell damage in the I / R model through the SIRT3 / FOXO3a / SOD2 signaling pathway, highlighting its heart-protecting function, and then exhibits the effects of inhibiting myocardial infarction and cardiac hypertrophy, lowering blood pressure, and inhibiting platelet aggregation. CN108553469A discloses the use of crocetin or its derivatives in the preparation of drugs for treating heart failure. Crocetin or its derivatives can significantly improve the left ventricular cardiac function of rats with chronic heart failure caused by coronary artery ligation, inhibit the secretion of angiotensin II, neuroendocrine factor NT-proBNP, and heart failure regulatory factor IL-6 in the over-activated renin-angiotensin-aldosterone system (RAAS) during heart failure, and inhibit myocardial pathological remodeling. The effects of some indicators are better than those of Qili Qiangxin Capsule. In order to improve the stability of crocetin and its derivatives, CN114748461B discloses a crocetin preparation and its application. The double-layer membrane structure of crocetin-loaded nanoliposomes has a good protective ability for crocetin molecules, which can not only protect crocetin molecules from digestion and decomposition in the harsh environment of the gastrointestinal tract, but also reduce the decomposition and destruction of crocetin under conditions such as light. However, its effect is to improve the anti-fatigue effect of crocetin.
[0005] The combination of nano drug carriers and modern medicine is an emerging discipline in the research of modern drug innovation. Compared with traditional small molecule drugs, nano drugs play a unique advantage in improving the drugability of drugs: 1) improving the pharmaceutical properties of drugs, such as increasing the solubility of drugs, improving the stability of drugs, etc.; 2) changing the in vivo pharmacokinetic parameters of drugs, such as extending the in vivo half-life of drugs and improving the targeting of drugs; 3) improving the therapeutic index of drugs, increasing the efficacy and reducing adverse reactions; 4) improving the utilization rate of drugs and reducing the toxic side effects of drugs on normal cells or tissues. At present, nanomaterials have been widely used in biological detection and in vitro diagnosis of diseases, and the safety of nano drugs directly applied to the human body requires higher requirements. Since nano drug preparations change the in vivo distribution behavior of the original drugs, they may cause new adverse reactions. These require comprehensive and in-depth toxicological studies of nano drug preparations.
[0006] Since sodium crocetin is very unstable in solution, has poor stability and absorption in the body, and has extremely low bioavailability, it is difficult to develop sodium crocetin into an oral preparation. In addition, the production cost of crocetin is high, and if the clinical daily dose is large, it will inevitably affect the drugability. Therefore, it is imperative to develop an efficient anti-heart failure nanoformulation of crocetin or its derivatives with good stability, high bioavailability, and oral administration. Summary of the invention
[0007] The present invention aims at the problems existing in the prior art, and provides a sodium crocetin nano complex preparation with high bioavailability, a preparation method, a drug and a use thereof. By using nanomaterials as drug carriers, CRAT is efficiently loaded and effectively released, and oral delivery of small molecule drugs is achieved. Compared with the traditional common CRAT, this improved nano preparation CRAT can greatly improve the stability, bioavailability and absorption efficiency of the drug, effectively improve the metabolism of the drug in the body, and can more effectively treat heart failure and other cardiovascular diseases, while improving various heart indicators, greatly expanding the clinical value and drugability of CRAT.
[0008] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0009] The invention provides a sodium crocetin nano complex preparation with high bioavailability. The complex preparation comprises sodium crocetin and a nano material. The nano material comprises a polymer nano carrier, a lipid nano carrier or an inorganic nano particle carrier.
[0010] Preferably, the polymer nanocarrier is selected from polylactic acid, polyglycolic acid, polylactic-co-glycolic acid, polycaprolactone, polyalkyl cyanoacrylate, polyhydroxybutyric acid (PHB), polyorthoester, polyanhydride, hydroxypropylmethylcellulose phthalate, polybutyl cyanoacrylate, chitosan (CTB), cell dextrin, sodium alginate, dextran or its derivatives.
[0011] Preferably, the lipid nanocarrier is selected from nanolipid particles, nanoliposomes, nanoemulsions, nanocapsules or polymer micelles.
[0012] Preferably, the inorganic nanoparticle carrier is selected from silica nanoparticles (SiNPs), gold nanoparticles (AuNPs), magnetic nanoparticles (MNPs), metal organic framework nanoparticles (MOFs), copper nanoparticles, iron oxide nanoparticles, carbon nanotubes (CNTs), nanodiamonds (NDs), fullerenes, hydroxyapatite nanoparticles or graphene oxide nanoparticles.
[0013] More preferably, the copper nanoparticles are copper silicate (CuSiO 3 ) nanoparticles.
[0014] Further preferably, the metal organic framework nanoparticles are γ-cyclodextrin metal organic framework (γ-CDMOFs) nanoparticles.
[0015] Preferably, the sodium crocetin is loaded on a nanomaterial.
[0016] Preferably, the mass ratio of the γ-cyclodextrin metal organic framework (γ-CDMOFs) nanoparticles to the sodium crocetin is 1-12:1.
[0017] The present invention also provides a method for preparing a sodium crocetin nano complex preparation, comprising the following steps:
[0018] (1) γ-cyclodextrin and KOH are dissolved in water, methanol is added in a volume ratio of water to methanol of 1-5:1, the mixture is heated to 60-80° C. until it becomes clear and stirred to obtain a solution A;
[0019] (2) dissolving polyethylene glycol 20000 in methanol and adding solution A to obtain a mixed solution;
[0020] (3) The mixed solution is heated and allowed to cool overnight to obtain a crude γ-cyclodextrin metal organic framework product;
[0021] (4) The crude product of γ-cyclodextrin metal organic framework is washed with methanol, centrifuged, activated with dichloromethane, and dried to obtain γ-cyclodextrin metal organic framework nanoparticles.
[0022] (5) The methanol solution of sodium crocetin is dispersed in the γ-cyclodextrin metal organic framework nanoparticles by rotary evaporation, and then ultrasonicated, stirred, and dried by rotary evaporation to obtain a sodium crocetin cyclodextrin metal organic framework complex preparation.
[0023] Preferably, the heating temperature in step (1) is 60-80° C., and stirring is performed while heating for 1-3 hours.
[0024] Preferably, the heating temperature in step (3) is 60-80° C., and the cooling temperature is room temperature.
[0025] Preferably, the solvent used for washing in step (4) is methanol, and the solvent used for activation is dichloromethane.
[0026] The present invention also provides a medicine for treating coronary heart disease, acute and chronic heart failure, cardiomyopathy, congenital heart disease, myocarditis, pericarditis or myocardial infarction, characterized in that the medicine comprises the sodium crocetin nanocomplex preparation and pharmaceutically acceptable excipients.
[0027] Preferably, the drug is in an oral dosage form or an injectable dosage form.
[0028] Further preferably, the oral dosage form is selected from tablets or capsules.
[0029] Preferably, the auxiliary material is one or more of a diluent, a disintegrant, a binder, and a lubricant.
[0030] Further preferably, the diluent is selected from one or more of microcrystalline cellulose, lactose, starch, dextrin and sucrose.
[0031] More preferably, the disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and dry starch.
[0032] Further preferably, the binder is selected from one or more of hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, povidone, and sodium carboxymethyl cellulose.
[0033] More preferably, the lubricant is one or more of magnesium stearate, calcium stearate, talcum powder, micro-powder silica, and silicon dioxide.
[0034] The present invention also relates to the use of the above-mentioned sodium crocetin nano complex preparation in the preparation of drugs for treating heart diseases, wherein the heart diseases include coronary heart disease, acute and chronic heart failure, cardiomyopathy, myocarditis, pericarditis or myocardial infarction.
[0035] Compared with the prior art, the present invention has the following beneficial effects:
[0036] (1) The present invention provides a sodium crocetin nanocomplex preparation, in which the process of dissolving and releasing CRAT loaded in nanomaterials is slower than that of CRAT alone. In addition, the drug detection rate of the nanoformulation enteric-coated capsule under accelerated conditions for 6 months does not change much, indicating that the nanocarrier-loaded CRAT can significantly improve the stability of CRAT. In the dissolution experiment of the embodiment, after 60 minutes, ordinary CRAT and CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT can all be completely dissolved, and CRAT is loaded in the nanocarrier, and the CRAT drug dissolution and release is more gentle, with a sustained release effect.
[0037] (2) Loading CRAT into nanomaterials can change the release and physicochemical properties of CRAT in the intestine and improve the bioavailability of CRAT absorbed in the body. In the examples, CDMOFs@CRAT increased the relative oral availability of CRAT by 198%. The drug exposure obtained by the two dosing sequences was compared, and the highest relative bioavailability of CDMOFs@CRAT could be increased by 287.5% and 376.7%, indicating that CDMOFs as a delivery carrier can significantly improve the bioavailability of CRAT drugs and improve drug metabolism.
[0038] (3) The sodium crocetin nanocomplex preparation can significantly delay the pathological enlargement of the left ventricular cavity caused by HFrEF, improve EF, FS and cardiac ejection function, significantly delay the development of HFrEF, have a more obvious inhibitory effect on myocardial fibrosis, and improve heart failure in rats.
[0039] (4) The sodium crocetin nanocomplex preparation showed a stronger positive regulatory effect than CRAT in reducing the levels of NT-proBNP, CK, LDH and the inflammation-related indicators IL-6 and TNF-α, indicating that 10 mg / kg dose of CDMOFs@CRAT is more capable of slowing down the progression of heart failure in multiple ways than 30 mg / kg dose of CRAT alone. The activity of CDMOFs@CRAT is more than 3 times higher than that of CRAT alone, which can more effectively alleviate the progression of heart failure and related cardiovascular diseases and improve various heart indicators. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 is the CRAT, γ-CD, and CDMOFs@CRAT in Example 3 1 H-NMR spectroscopy;
[0041] Figure 2 SEM images of CDMOFs and CDMOFs@CRAT in Example 3;
[0042] Figure 3 Representative SEM elemental mapping images of CDMOFs and CDMOFs@CRAT in Example 3;
[0043] Figure 4 Elemental spectra of CDMOFs and CDMOFs@CRAT in Example 3;
[0044] Figure 5 XPS spectra of CDMOFs and CDMOFs@CRAT in Example 3
[0045] Figure 6 XRD spectra of γ-CD, CDMOFs, CRAT, and CDMOFs@CRAT in Example 3;
[0046] Figure 7 The dissolution curves of CRAT, CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT, and PHB@CRAT in Example 5;
[0047] Figure 8Characteristic analysis of CDMOFs@CRAT in Example 7, wherein A is the state of CRAT and CDMOFs@CRAT at room temperature at different concentrations; B is the SEM image of CDMOFs after incubation in pH 6.8 solution for 30 minutes; C is the SEM image of CRAT after incubation in pH 6.8 solution for 30 minutes; D is the SEM image of CDMOFs@CRAT after incubation in pH 6.8 solution for 30 minutes;
[0048] Fig. 9 Schematic diagram of the pharmacodynamic study of CRAT and CDMOFs@CRAT in the coronary artery ligation rat model of Example 9;
[0049] Fig.10 The representative results and score measurement analysis of the levels of markers associated with heart failure in rat serum in Example 9;
[0050] Fig.11 The results of Example 9, using Masson staining, show the inhibitory effect of CRAT and CDMOFs@CRAT administration on the production of myocardial collagen fibers. DETAILED DESCRIPTION
[0051] It is worth noting that the raw materials used in the present invention are all common commercially available products, and their sources are not specifically limited.
[0052] Explanation of technical terms:
[0053] γ-CDMOFs, i.e. CDMOFs: γ-cyclodextrin metal-organic framework;
[0054] γ-CD: γ-cyclodextrin;
[0055] CRAT: Crocetin sodium;
[0056] CDMOFs@CRAT: Sodium Crocetin γ-cyclodextrin Metal-Organic Framework Complex Formulation;
[0057] AuNRs@CRAT: sodium crocetin gold nanoparticle complex formulation;
[0058] CuSiO3@CRAT: Sodium Crocetin Copper Silicate Nanoparticle Complex Formulation;
[0059] CTS@CRAT: sodium crocetin chitosan nanocomplex formulation;
[0060] PHB@CRAT: sodium crocetin polyhydroxybutyrate nanocomplex formulation.
[0061] Example 1 Preparation of sodium crocetin nanocomplex preparation
[0062] (1) Sodium Crocetin γ-cyclodextrin metal organic framework complex preparation
[0063] 1gγ-cyclodextrin and 0.35g KOH were added to 31mL ultrapure water, fully dissolved, and 10mL of methanol was added to obtain a cyclodextrin methanol solution. The cyclodextrin methanol solution was passed through a nylon 6 filter (0.22μm) and stirred in a 60°C water bath for 1 hour. 0.62g PEG20000 (polyethylene glycol 20000) was dissolved in 3.1mL methanol to obtain a PEG20000 methanol solution, which was then slowly added to the cyclodextrin methanol solution. The mixed solution continued to be stirred in a 60°C water bath for 10 minutes, and then it was allowed to stand and cool at room temperature for 12 hours overnight to obtain a crude γ-CDMOFs product. The crude product was washed with methanol. After centrifugation, it was soaked in 10mL of dichloromethane for activation overnight. The solid was then recovered by centrifugation and dried to obtain a γ-CDMOFs sample.
[0064] The dried γ-CDMOFs (8 g) were dispersed in 16 L (4 times of rotary evaporation, 4 L each time) CRAT methanol (0.1% NaOH) solution (3.1 g, 4 L, 0.77 g / L) and ultrasonicated for 5 min, then stirred for 1 h. Then, the solution was rotary evaporated at room temperature (25 ° C) until it was dry, and the solid was transferred to the centrifuge tube in batches. The remaining material on the wall of the glass bottle was transferred to the sample centrifuge tube in batches through 800 mL of methanol, and the supernatant was removed by centrifugation (9500 rpm, 10 min, 4 ° C), and washed with 1000 mL of methanol in batches 4 times. Then, it was dried in a vacuum drying oven overnight (16 h) to obtain the final product, sodium crocetin γ-cyclodextrin metal organic framework complex preparation CDMOFs@CRAT.
[0065] (2) Complex preparation of sodium crocetin gold nanoparticles
[0066] Place 10 mL of 0.2 mol / L hexadecyltrimethylammonium bromide aqueous solution in a 25°C constant temperature water bath and add 5×10 -4 1 mL of 0.01 mol / L chloroauric acid aqueous solution was added, and the solution turned brown after stirring. Then 1 mL of 0.01 mol / L icy sodium borohydride aqueous solution was added to the above solution. After rapid stirring for 2 minutes, it was placed in a water bath at this temperature to obtain a gold nanoparticle seed solution.
[0067] Place 10 mL of 0.2 mol / L hexadecyltrimethylammonium bromide aqueous solution in a 25°C constant temperature water bath and add 4×10 -3 mol / L silver nitrate solution 1mL, stir evenly and then add 1×10 -31 mL of mol / L chloroauric acid aqueous solution was added, and the solution changed from colorless to brown-yellow after being stirred evenly. Then, 0.0788 mol / L ascorbic acid aqueous solution was added to the mixed solution, and the mixture was stirred rapidly until the mixed solution became colorless. This was called the growth solution.
[0068] Add 30 ml of seed solution to 10 ml of growth solution, mix well and place in a 30 ° C water bath. The solution changes from colorless to dark red in about 5 minutes. Continue to place in the water bath under this condition for 12 hours to obtain a gold nanorod aqueous solution. 4 mg of CRAT was ultrasonically dissolved in methanol (0.1% NaOH) solution, and the methanol was removed by rotary evaporation under reduced pressure to form a transparent film in a round-bottom flask. 4 mL of gold nanorod aqueous solution was added and continued to rotate for hydration. After complete hydration, it was ultrasonically dissolved again, and the mixture was probed 40 times in an ice bath in an ultrasonic cell crusher. It was centrifuged at 8000 r / min for 10 minutes, the precipitate was discarded, vortexed for 1 minute, and the reaction was shaken on a shaker at room temperature for 12 hours to obtain sodium crocetin gold nanoparticles AuNRs@CRAT.
[0069] (3) Complex preparation of sodium crocetin copper silicate nanoparticles
[0070] Hexadecyl trimethyl ammonium bromide (0.18g) and ammonium fluoride (0.3g) were dissolved in 45mL deionized water. After 1 hour of magnetic stirring at 80℃, a mixed solution of ethyl orthosilicate (1mL) and ethanol (4mL) was slowly added to the above solution. After 4 hours of magnetic stirring at 80℃, the synthesized nanospheres were collected by centrifugation (9000rpm, 5 minutes) and washed three times with ethanol. After the product was freeze-dried for 48 hours, mesoporous silica nanospheres with a size of about 80-120nm were obtained. Mesoporous silica (10mg) was added to 10mL deionized water and ultrasonically dispersed to form a white emulsion; copper acetate (10mg) and disodium maleate (100mg) were dissolved in 10mL deionized water, the two solutions were mixed evenly, and ultrasonically stirred for 30 minutes. The mixed emulsion was transferred to a stainless steel autoclave lined with polytetrafluoroethylene, kept at 140°C for 12 hours, cooled to room temperature, centrifuged (9000rpm, 5 minutes), and washed three times with deionized water to obtain the product CuSiO3. 8 mg of the prepared copper silicate nanoparticles were added to ethanol (5 mL) and ultrasonicated for 10 minutes to form a uniform dispersion. Then, 2 mg of CRAT and 1 mg of distearoylphosphatidylethanolamine-polyethylene glycol-amino crosslinked product DSPE-PEG-NH2 were added to ethanol (5 mL), the two solutions were mixed evenly, and magnetically stirred at room temperature for 6 hours. After centrifugation (9000rpm, 5 minutes), the CuSiO3@CRAT nanoparticles were washed three times with ethanol and water.
[0071] (4) Sodium Crocetin Chitosan Nanocomplex Preparation
[0072] 8g chitosan (CTS) was added to 40mL of 1% acetic acid solution, stirred for 1 hour, and after the chitosan was completely dissolved, the solution was passed through a 0.22μm filter paper. 5g sodium tripolyphosphate was added to 40mL of deionized water, stirred for 30 minutes, and after the sodium tripolyphosphate was completely dissolved, the solution was passed through a 0.22μm filter paper. 2g CRAT was ultrasonically dissolved in methanol (0.1% NaOH) solution, and then added dropwise to the chitosan solution. Under continuous magnetic stirring, the sodium tripolyphosphate solution was slowly added dropwise to the solution, and stirred for 30 minutes to form chitosan nanoparticles loaded with CRAT. Subsequently, the mixture was centrifuged at a speed of 12000 rpm, and the effluent was freeze-dried in a freeze dryer to obtain chitosan nanoparticle powder CTS@CRAT loaded with CRAT.
[0073] (5) Sodium Crocetin Polyhydroxybutyrate Nanocomplex Preparation
[0074] Weigh 3g of polyhydroxybutyric acid (PHB) and dissolve it in 100mL of methanol. Dissolve it under magnetic stirring at room temperature until it is completely dissolved. Add 0.3g of CRAT and continue magnetic stirring for 10 minutes until it is evenly dissolved to form an organic phase. Weigh 30g of polyvinyl alcohol and dissolve it in 1000mL of water. Dissolve it at high temperature for 1 hour until it is completely dissolved and cool to room temperature to form an aqueous phase. Take out 2ml of the above organic phase and 200mL of the aqueous phase and place them in a dry beaker. Ultrasonic treatment at 100W for 10 minutes forms an emulsion. Immediately pour the emulsion into a rotary evaporator to remove methanol. After 1 hour, high-speed centrifugation and resuspend the nanoparticles to obtain sodium crocetin polyhydroxybutyric acid nanoparticles PHB@CRAT.
[0075] Example 2 Determination of particle size, encapsulation efficiency and yield
[0076] The drug encapsulation efficiency and loading amount were calculated by weighing the solution concentration (HPLC) before the reaction. The particle size of the nanoparticle preparation was determined by a laser nanoparticle size analyzer.
[0077] Calculation of drug loading and yield: Weigh 5 mg of the active substance powders of CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT prepared in Example 1 respectively, and prepare 50 μg / mL solution. The loading amount of CRAT in the γ-CDMOFs carrier was quantified by HPLC and the loading efficiency was calculated. Taking CDMOFs as an example, other nanoformulations were replaced accordingly, and the drug encapsulation rate and yield were calculated by the following formula.
[0078]
[0079]
[0080]
[0081] The results are shown in Table 1.
[0082] Table 1 Particle size, encapsulation efficiency and yield data of complex preparations of sodium crocetin
[0083]
[0084] Example 3 Characterization of complex preparation of sodium crocetin γ-cyclodextrin metal organic framework
[0085] After mixing γ-cyclodextrin and potassium ions in a round-bottom flask by hydrothermal method, the formation of γ-CDMOFs crystal nuclei was controlled by adding PEG20000 as an activator to limit the size of crystal particles. Figure 1 As shown. 1 In the H-NMR spectrum ( Figure 1 ), the characteristic signals of the substance are at 5.12ppm and 3.5-4ppm, respectively, of which 4.79ppm is the peak of heavy water solvent. Through analysis, the characteristic peak at 5.12ppm is the hydrogen atom at position 1 on the five-membered ring. Due to the influence of the two oxygen atom electron-withdrawing groups, the electron cloud density around the hydrogen atom is reduced, so it is the H with the largest value in the chemical shift. The other hydrogen atoms at positions 2, 3, 4, 5, and 6 are mainly distributed in the range of 3.5-4ppm. Comparing the nuclear magnetic hydrogen spectra of γ-cyclodextrin and γ-CDMOFs, it can be found that the characteristic absorption peaks of the two are basically consistent, indicating the successful synthesis of γ-CDMOFs. In addition, since the H on the OH functional group is inactive hydrogen, no absorption peak appears in the spectrum, which may be due to the exchange of deuterated hydrogen in the solvent D2O. In the nuclear magnetic hydrogen spectrum of CDMOFs@CRAT, the present invention also clearly observed the characteristic absorption belonging to γ-CDMOFs. In addition, the characteristic absorption of CRAT is at 6-7ppm, which shows the successful loading of CRAT. 1 The measurement conditions of H-NMR spectrum were as follows: solvent (D2O, 1% NaOH), 25°C.
[0086] The present invention also uses SEM surface electron microscope scanning and surface element positioning to confirm the changes in the morphology, size, and dimensions of γ-CDMOFs and CDMOFs@CRAT. It can be seen from the SEM characterization result diagram that ( Figure 2), the γ-CDMOFs crystal particles have a regular cubic morphology, a smooth surface, and a size of approximately less than 10 μm. The uneven size of the crystals may be due to the fact that the formation and speed of the nucleus growth are affected by the solvent and temperature. The energy spectrum data proves that the γ-CDMOFs crystals contain C, O, and K elements, indicating the successful synthesis and purity of γ-CDMOFs. The SEM-EDS results of CDMOFs@CRAT show no obvious difference in size from the structure of the γ-CDMOFs crystals. After drug loading, the present invention can observe that the surface of γ-CDMOFs is no longer smooth, and the Na element can also be clearly observed in the EDS results ( Figure 3 , Figure 4 ). Since SEM is a means of detecting the surface of a material, a large part of the adsorbed CRAT may be adsorbed into the internal pores of γ-CDMOFs. The present invention cannot judge the loading amount of CRAT based on this result, but the loading behavior has no obvious effect on the crystal size of the γ-CDMOFs carrier, confirming the feasibility of this loading scheme. At the same time, the experimental results of XPS further confirmed that C and O are the main components of γ-CDMOFs. In the elemental composition of CRAT@CDMOFs, the appearance of the Na element of CRAT was clearly observed, confirming the successful loading of CRAT. It is worth mentioning that the reason why the K element is not displayed on the XPS spectrum is because the detection intensity of the K element is low in the pores of γ-CDMOFs ( Figure 5 ).like Figure 6 As shown in the figure, γ-CDMOFs and CDMOFs@CRAT have obvious crystal diffraction peaks in the range of 5°-30°. From the results, the characteristic peaks of the X-ray powder diffraction data of γ-CDMOFs and the characteristic diffraction peaks of CDMOFs@CRAT are basically consistent in peak shape, indicating that the behavior of drug loading has no effect on the crystallinity of the crystal carrier. The characteristic diffraction peaks of CRAT can be observed in the diffraction results of CDMOFs@CRAT, which confirms the successful synthesis of CRAT@CDMOFs.
[0087] Example 4 Preparation of enteric-coated capsule preparation
[0088] CRAT enteric-coated capsule preparation: 40 mg CRAT and 214.4 mg lactose were weighed into a PE bag, mixed for 5 min, and then sieved through a 60-mesh sieve twice. Then, 40 mg pregelatinized starch, 16 mg low-substituted hydroxypropyl cellulose, and 6.4 mg silicon dioxide were added, mixed for 5 min, and then sieved through a 60-mesh sieve. Finally, 3.2 mg magnesium stearate was added and mixed for 3 min to obtain the total mixture, which was filled into CRAT enteric-coated capsules.
[0089] CDMOFs@CRAT enteric-coated capsule preparation: weigh 66.67 mg of CDMOFs@CRAT and 142.93 g of lactose into a PE bag, mix for 5 minutes, and then pass through a 60-mesh sieve twice. Then, add 84.8 mg of pregelatinized starch, 16 mg of low-substituted hydroxypropyl cellulose, and 6.4 mg of silicon dioxide, mix for 5 minutes, and pass through a 60-mesh sieve. Finally, add 3.2 mg of magnesium stearate and mix for 3 minutes to obtain the total mixture, which is then filled into CDMOFs@CRAT enteric-coated capsules.
[0090] The formula of CRAT and CDMOFs@CRAT enteric-coated capsule preparations is shown in Table 2. The preparation methods of AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT enteric-coated capsules refer to the preparation process of the above-mentioned CDMOFs@CRAT enteric-coated capsules.
[0091] Table 2 Formulation of CRAT and CDMOFs@CRAT enteric-coated capsules
[0092]
[0093] Example 5 Dissolution Experiment
[0094] Refer to the dissolution and release determination method (Method 2 of Part IV of the Chinese Pharmacopoeia 2020 Edition, General Rules 0931): Take 5 capsules of each of the CRAT enteric gel and CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT nano enteric capsules prepared in Example 4, and use 900 mL of 0.1 mol / L hydrochloric acid solution as the dissolution medium. The paddle method speed is 50 revolutions per minute. After 120 minutes, the acid solution in each dissolution cup is discarded, and 900 mL of pH 7.8 phosphate buffer at 37°C±0.5°C is immediately added. The speed remains unchanged, and 10 mL of the dissolution solution is taken at 10 minutes, 15 minutes, 30 minutes, 45 minutes, 60 minutes, 90 minutes, and 120 minutes, respectively, and 10 mL of 37°C±0.5°C dissolution medium is replenished in time. Filter with a 0.45μm water filter, discard 5mL of the primary filtrate, accurately measure 1mL of the subsequent filtrate and place it in a 20mL volumetric flask, add pH 7.8 phosphate buffer to dilute to the scale, shake well, measure the absorbance at a wavelength of 421nm, and calculate the dissolution amount of each particle.
[0095] Calculation formula:
[0096]
[0097]
[0098] Note: When t = 1, the cumulative dissolution (t)% is equal to the dissolution (t)%;
[0099] Where:
[0100] A t —Absorbance of the test solution at time point t; A 对 —Absorbance of reference solution;
[0101] f—correction factor; —average correction factor;
[0102] m 对 —Weighing amount of reference substance, mg; V 对 —Dilution volume of reference substance, mL;
[0103] P—the content of the reference substance; V0—the initial volume of the dissolution medium, mL;
[0104] V1—sampling volume, mL; V2—replenishment volume, mL;
[0105] n—the number of sampling time points; t—the tth sampling point;
[0106] M r —Labeled strength of the test sample, mg.
[0107] The present invention studied the dissolution of CRAT alone and CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT nanoformulations in a simulated small intestinal physiological environment (pH 7.8 PBS solution). Figure 7 It can be observed that the dissolution and release of CRAT loaded in CDMOFs, AuNRs, CuSiO3, CTS and PHB nanoparticles is slower than that of CRAT alone. CRAT alone is almost 100% dissolved after 30 minutes, but nanoformulations such as CDMOFs@CRAT only dissolve 50-70% at the same time. It is not until nearly 60 minutes later that the CRAT drug in CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT nanoformulations is completely dissolved. It can be seen that the dissolution and release of CRAT drugs loaded in nanoparticles CDMOFs, AuNRs, CuSiO3, CTS and PHB are more gentle, and the nanoformulations have a certain drug sustained release effect.
[0108] Example 6 Accelerated stability test
[0109] The CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT nano enteric capsules prepared in Example 4 were subjected to an accelerated stability test. The nanoformulations were placed in a stable box at a temperature of 30°C ± 2°C and a relative humidity of 75% ± 5% for half a year, and samples were taken at 1, 2, 3, and 6 months of acceleration to detect the content of CRAT. The detection method was high performance liquid chromatography, using a C18 chromatographic column (4.6mm×200mm, 5μm), a mobile phase of methanol: water: glacial acetic acid (75:24.5:0.5), a flow rate of 1.0mL / min, a column temperature of 30°C, a detection wavelength of 423nm, and the CRAT content was calculated using the area normalization method. The results are shown in Table 3.
[0110] The results of the accelerated stability test show that the CRAT nanoformulation enteric-coated capsules prepared by the present invention have good stability under accelerated conditions. The content was detected by HPLC, which showed that there was no obvious degradation phenomenon under accelerated conditions of half a year. Compared with ordinary CRAT enteric-coated capsules, the nanoformulations CDMOFs@CRAT, AuNRs@CRAT, CuSiO3@CRAT, CTS@CRAT and PHB@CRAT have good drug stability.
[0111] Table 3 Accelerated stability test data
[0112]
[0113] Example 7 Characteristic Analysis of CDMOFs@CRAT
[0114] Characteristic analysis of CDMOFs@CRAT Figure 8 As shown, A is the state of CRAT and CDMOFs@CRAT at different concentrations at room temperature. In addition, in order to verify the stability of CRAT in the physiological environment of the duodenum after loading, the present invention incubated γ-CDMOFs, CRAT, and CRAT@CDMOFs in an acidic environment of pH 6.8, and observed the changes in morphology by SEM. Figure 8 Figure B shows that although the surface of the γ-CDMOFs crystals collapses to a certain extent in acidic conditions, the overall morphology of the crystals remains the same; Figure 8 C in the figure shows that CRAT alone has completely agglomerated and flaked in a slightly acidic environment; Figure 8Figure D shows that in an acidic environment, although the CRAT drug in CDMOFs@CRAT has been released and crystallized, it is still around the surface of the γ-CDMOFs carrier instead of forming a sheet structure. This morphological change after loading can significantly increase the specific surface area of CRAT, which is beneficial to the drug absorption of CRAT in the intestine and the metabolism of the drug in the body. Loading CRAT into γ-CDMOFs to form CDMOFs@CRAT not only has a certain drug sustained release effect, but also has a favorable effect on the intestinal absorption and oral availability of CRAT.
[0115] Example 8 CDMOFs@CRAT Drug Metabolism Analysis
[0116] Animal source, animal husbandry and ethics number: 6 ordinary female Beagle dogs weighing 12-16 kg, from the reserve dogs of Boji Medical Drug Evaluation Center (experimental animal use license number: SYXK (Guangdong) 2022-0279), experimental animal quality certificate number: No. 110334210100040471, No. 370825220100019471. Six ordinary female Beagle dogs weighing 12-16 kg were used, sorted by weight, and randomly divided into two groups, 3 in each group A and B (numbered A1, A2, A3, B1, B2, B3, respectively). The drugs were administered after meals, and the administration method was oral. The drugs were cross-administered in two cycles for 7 days, and the ordinary CRAT enteric-coated capsules and CDMOFs@CRAT enteric-coated capsules prepared in Example 4 were given respectively; the drugs were administered once per cycle, 1 capsule each time. See the table below for cross-administration:
[0117] Table 4 Two-period crossover dosing design
[0118]
[0119] Blood samples were collected from the two groups of animals before and 15min, 30min, 1h, 2h, 3h, 4h, 6h, 8h, 10h, 12h, 18h, and 24h after administration. About 2mL of whole blood was collected from the cephalic vein of the forelimb into a heparinized blood collection tube, centrifuged at 4500rpm for 10min, and the plasma was separated and temporarily stored in an ultra-low temperature refrigerator for testing. The concentration of crocetin in plasma was determined using the validated UPLC method. The blood drug concentration data was processed using DAS 3.3.0, and the main pharmacokinetic parameters were calculated using a non-compartmental model. The parameters of different preparations of sodium crocetin (CRAT) were compared to obtain the relative bioavailability of different preparations.
[0120] The specific results are shown in Tables 5-7. From the data in the tables, it can be seen that the half-life of the two drugs of the present invention is t 1 / 2 By CRATt 1 / 2 The t of CDMOFs@CRAT was 2.466±0.517h.1 / 2 The drug concentration peak time Tmax was extended from 2.37h of CRAT to 3.33h of CDMOFs@CRAT, which was 40% longer, and the drug peak concentration Cmax of CDMOFs@CRAT was significantly improved, 1260.302μg / L for CRAT and 2188.522μg / L for CDMOFs@CRAT, which was 1.74 times that of CRAT. It can be seen that based on the same concentration of active drugs, CDMOFs@CRAT has better absorption effect and longer action time in the body. It can be seen that regardless of whether CRAT or CDMOFs@CRAT is taken orally first, the plasma exposure AUC12134.13μg / L*h of CDMOFs@CRAT is significantly higher than 7303.27μg / L*h of CRAT, and CDMOFs@CRAT is 1.66 times that of CRAT; in addition, the drug exposure AUC obtained by the two dosing sequences is compared, and the highest relative bioavailability of CDMOFs@CRAT in the two groups of animals can be increased by 287.5% and 376.7%, respectively, and the relative oral availability of CDMOFs@CRAT is increased by 198% compared with CRAT. The above experimental results confirm that compared with CRAT, CDMOFs@CRAT has improved peak concentration and peak time, significantly improving the in vivo bioavailability of sodium crocetin.
[0121] Table 5 Pharmacokinetic parameters of CRAT enteric-coated capsules
[0122]
[0123] Table 6 Pharmacokinetic parameters of CDMOFs@CRAT enteric-coated capsules
[0124]
[0125] Table 7 Relative oral bioavailability of CRAT and CDMOFs@CRAT enteric-coated capsules
[0126]
[0127] Example 9 CDMOFs@CRAT efficacy analysis
[0128] Animal source, animal husbandry and ethics number: 170.6-258.1g SD rats, SPF grade, 105, 5-7 weeks, male. Surplus animals will be euthanized after the experiment. Purchased from Guangdong Weitonglihua Laboratory Animal Technology Co., Ltd., the laboratory animal production license number is: SCXK (Yue) 2022-0063, and the laboratory animal quality certificate number is No. 44829700004834.
[0129] SD rats were subjected to coronary artery ligation to induce chronic heart failure with reduced ejection fraction (HFrEF) modeling, so as to investigate the therapeutic effects of ordinary CRAT enteric-coated capsules (low and high doses) and CDMOFs@CRAT enteric-coated capsules prepared in Example 4 on HFrEF. Except for 8 rats in the sham operation group, the remaining rats underwent coronary artery ligation. The sham operation group only had threading without ligation, and were routinely fed for 8 weeks after surgery. Subsequently, the animals with ejection fraction (EF) <50% were randomly divided into model control group, CRAT low-dose group, CRAT high-dose group, and CDMOFs@CRAT group. Intragastric administration was started. For details, see Table 8, once a day for 5 consecutive weeks. During the treatment period, there was no significant difference in animal body weight among the groups. Echocardiography and blood biochemical tests were performed in the 5th week of administration, including serum N-terminal pro-brain natriuretic peptide (NT-proBNP), creatine kinase (CK), and lactate dehydrogenase (LDH), and the heart was taken for HE and Masson staining. For specific results, see Figure 9-11 .
[0130] Table 8 Drug administration in different experimental groups
[0131]
[0132] In order to evaluate the ability of CRAT and CDMOFs@CRAT to regulate cardiac function in HFrEF rats, the cardiac-related parameters in echocardiograms of each group were compared at the 5th week of administration. Fig. 9Comparative analysis showed that compared with the model control group, the ejection fraction (EF) and fractional shortening (FS) in the low-dose CRAT group showed an upward trend, while the left ventricular end diastolic dimension (LVDd) and left ventricular end systoledimension (LVDs) showed a downward trend; the EF and FS in the high-dose CRAT group showed an upward trend, while LVDd and LVDs showed a downward trend. In the CDMOFs@CRAT group, LVDs was significantly reduced (p<0.05), EF and FS were significantly increased (p<0.05), and LVDd showed a downward trend. At the same time, the results showed that the EF and FS of CDMOFs@CRAT were higher than those of the low- and high-dose CRAT groups, and LVDs and LVDd were lower than those of the low- and high-dose CRAT groups. The above results show that CRAT can significantly delay the pathological enlargement of the left ventricular cavity caused by HFrEF, improve EF and FS to a certain extent, and improve cardiac ejection function. Among them, CDMOFs@CRAT has more significant improvement effects on various indicators of cardiac function than the low and high dose groups of CRAT, and 10 mg / kg dose of CDMOFs@CRAT can more effectively alleviate the onset of heart failure and improve various indicators of heart failure than 30 mg / kg dose of CRAT alone. The activity of CDMOFs@CRAT is more than 3 times higher than that of CRAT alone, achieving unexpected technical effects.
[0133] The present invention analyzes the level of N-terminal pro-brain natriuretic peptide (NT-proBNP) in rat serum, which is a marker associated with heart failure. Fig.10The data can be analyzed to know that compared with the sham operation group, the model control group showed an increasing trend. Compared with the model control group, the NT-proBNP levels in the CRAT high-dose group and the CDMOFs@CRAT group showed a significant downward trend, and the NT-proBNP level of CDMOFs@CRAT was significantly lower than that of the CRAT low-dose group and lower than that of the CRAT high-dose group, almost reaching the level of the normal model group. At the same time, the present invention also detected the levels of CK and LDH, representative substances of myocardial injury, to explore the protective effects of CRAT and CDMOFs@CRAT on myocardial injury. Compared with the sham operation group, the CK and LDH levels in the serum of the model control group were significantly increased; compared with the model control group, the serum CK and LDH levels of the CRAT low-dose group, the CRAT high-dose group, and the CDMOFs@CRAT group were observed to be significantly reduced, and the serum CK and LDH levels of the CDMOFs@CRAT group were significantly lower than those of the CRAT low-dose group and the high-dose group, and even lower than those of the sham operation control group. The serum CK and LDH values of 10mg / kg CDMOFs@CRAT were not only significantly lower than those of 10mg / kg CRAT, but also significantly lower than those of 30mg / kg CRAT. The results of this study indicate that 10mg / kg CDMOFs@CRAT has a stronger effect on improving heart failure and treating myocardial injury than 30mg / kg CRAT.
[0134] The present invention also observed the inhibitory effect of CRAT and CDMOFs@CRAT on myocardial collagen fiber production by Masson staining. Fig.11 As shown. Compared with the sham control group, the Masson staining positive area in the model control group, CRAT and CDMOFs@CRAT groups increased significantly, showing obvious myocardial fibrosis. At the same time, all CRAT administration groups can reduce the Masson staining positive area, indicating that the degree of myocardial fibrosis has been effectively improved; among them, the positive area of the CDMOFs@CRAT group is smaller than that of the low-dose CRAT and high-dose groups, and has a significant improvement compared with the model control group, indicating that CRAT has a more obvious inhibitory effect on myocardial fibrosis, especially CDMOFs@CRAT has a stronger inhibitory effect on myocardial fibrosis than conventional CRAT enteric-coated capsules.
[0135] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A sodium crocetin nanocomplex preparation with high bioavailability, characterized in that: The sodium crocetin nano complex preparation comprises sodium crocetin and nano materials, wherein the nano materials comprise polymer nano carriers, lipid nano carriers or inorganic nano particle carriers.
2. The sodium crocetin nanocomplex preparation according to claim 1, characterized in that: The polymer nanocarrier is selected from polylactic acid, polyglycolic acid, polylactic coglycolic acid, polycaprolactone, polyalkyl cyanoacrylate, polyhydroxybutyric acid, polyorthoester, polyanhydride, hydroxypropyl methylcellulose phthalate, polybutyl cyanoacrylate, chitosan, cell dextrin, sodium alginate or dextran; the lipid nanocarrier is selected from nanolipid particles, nanoliposomes, nanoemulsions or nanocapsules; the inorganic nanoparticle carrier is selected from silica nanoparticles, gold nanoparticles, magnetic nanoparticles, metal organic framework nanoparticles, copper nanoparticles, iron oxide nanoparticles, carbon nanotubes, nanodiamonds, fullerenes, hydroxyapatite nanoparticles or graphene oxide nanoparticles; further preferably, the copper nanoparticles are copper silicate nanoparticles.
3. The sodium crocetin nanocomplex preparation according to claim 2, characterized in that: The metal organic framework nanoparticles are γ-cyclodextrin metal organic framework nanoparticles.
4. The sodium crocetin nanocomplex preparation according to claim 3, characterized in that: The mass ratio of the γ-cyclodextrin metal organic framework nanoparticles to the sodium crocetin is 1-12:
1.
5. The sodium crocetin nanocomplex preparation according to claim 1, characterized in that: The sodium crocetin is loaded on the nano material.
6. A method for preparing the sodium crocetin nanocomplex preparation according to claim 3 or 4, characterized in that: The preparation method comprises the following steps: (1) γ-cyclodextrin and KOH are dissolved in water, methanol is added in a volume ratio of water to methanol of 1-5:1, the mixture is heated to 60-80° C. until it becomes clear and stirred to obtain a solution A; (2) dissolving polyethylene glycol 20000 in methanol and adding solution A to obtain a mixed solution; (3) The mixed solution is heated and allowed to cool overnight to obtain a crude γ-cyclodextrin metal organic framework product; (4) The crude product of γ-cyclodextrin metal organic framework is washed with methanol, centrifuged, activated with dichloromethane, and dried to obtain γ-cyclodextrin metal organic framework nanoparticles; (5) The methanol solution of sodium crocetin is dispersed in the γ-cyclodextrin metal organic framework nanoparticles by rotary evaporation, and the mixture is sonicated, stirred, and dried by rotary evaporation to obtain a sodium crocetin cyclodextrin metal organic framework complex preparation.
7. A drug for treating heart disease, characterized in that: The drug comprises the sodium crocetin nanocomplex preparation according to any one of claims 1 to 5 and pharmaceutically acceptable excipients, and the heart disease comprises coronary heart disease, acute and chronic heart failure, cardiomyopathy, myocarditis, pericarditis or myocardial infarction.
8. The drug according to claim 7, characterized in that The dosage form of the drug is an oral dosage form or an injection dosage form; preferably, the oral dosage form is selected from tablets or capsules.
9. The drug according to claim 7, characterized in that The auxiliary material is selected from one or more of a diluent, a disintegrant, a binder, and a lubricant; The diluent is selected from one or more of microcrystalline cellulose, lactose, starch, dextrin, and sucrose; The disintegrant is selected from one or more of cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and dry starch; The binder is selected from one or more of hydroxypropyl methylcellulose, methyl cellulose, ethyl cellulose, povidone, and sodium carboxymethyl cellulose; The lubricant is one or more of magnesium stearate, calcium stearate, talcum powder, micro-powder silica gel and silicon dioxide.
10. Use of the sodium crocetin nanocomplex preparation according to any one of claims 1 to 5 or the sodium crocetin nanocomplex preparation obtained by the preparation method according to claim 6 or the drug according to any one of claims 7 to 9 in the preparation of drugs for treating heart diseases, wherein the heart diseases include coronary heart disease, acute and chronic heart failure, cardiomyopathy, myocarditis, pericarditis or myocardial infarction.
Citation Information
Patent Citations
Application of crocetin or derivative thereof in preparing medicine for treating heart failure
CN108553469A
Cyclodextrin-metal organic framework composition for improving medicine solubility
CN110314241A
Crocetin preparation and application thereof
CN114748461A
Application of crocetin in preparation of medicine for treating and preventing cerebral ischemic diseases
CN116019802A
Curcumin drug loading system and preparation method thereof
CN116211839A
Cited By
Crocetin preparation with high bioavailability and application thereof
CN118845791A
A crocetin preparation with high bioavailability and its application
CN118845791B
8-hydroxyquinoline iron-loaded CS-TPP nano microcapsule as well as preparation method and application thereof
CN120661479A
Crocetin preparation with high bioavailability, and use thereof
WO2025260444A1
